Recombinant vector technologies can improve the yield and lower the cost of egg-based influenza vaccine production.
Eluemuno R. Blyden, PhD
Advertisement
Eluemuno R. Blyden, PhD, is the founder and CEO of AfriVax, Inc.
Articles by Eluemuno R. Blyden, PhD
Advertisement
Latest Updated Articles
New Approaches to Improved Vaccine Manufacturing in Embryonated EggsPublished: January 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
